Erweiterte Suche

Zurzeit bekleidet Katharine Knobil die Position des Chief Medical Officer von Agilent Technologies, Inc. Dr. Knobil ist außerdem Mitglied des Vorstands von Arena Pharmaceuticals, Inc. und Mitglied der National Academies of Science. Zuvor hatte Dr. Knobil die Position des Chief Medical Officer, Head-Research & Development bei Kaleido Biosciences, Inc. und Chief Medical Officer & Senior Vice President bei GlaxoSmithKline LLC inne. Dr. Knobil erwarb einen Bachelor-Abschluss an der Cornell University und einen Doktortitel am The University of Texas Southwestern Medical Center.

Katherine Knobil currently works at ViiV Healthcare Ltd., as Director from 2017.

Ms. Katharine J.
O'Donovan is a Portfolio Manager at FMR Investment Management (UK) Ltd.
She joined the firm in May 2008 as a Research Analyst for the European bank sector.
Prior to joining FMR, Ms. O’Donovan spent 10 years each on the buy side and sell side evaluating at European banks, and subsequently global financials.
She was at First State Investments from 2007 through 2008 researching financials on the global team.
From 1999 to 2007, Ms. O’Donovan covered European banks including the UK at Credit Suisse Asset Management.
From 1989 to 1999, she was a sell side analyst of European banks, at what is now Deutsche Bank.